dipyridamole has been researched along with Asphyxia Neonatorum in 1 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
Asphyxia Neonatorum: Respiratory failure in the newborn. (Dorland, 27th ed)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Heynen, U | 1 |
1 other study available for dipyridamole and Asphyxia Neonatorum
| Article | Year |
|---|---|
[Persantin: coronary insufficiency, prevention of thrombosis, kidney failure, intrauterine asphyxia].
Topics: Animals; Asphyxia Neonatorum; Attitude; Coronary Circulation; Coronary Disease; Dipyridamole; Female | 1972 |